Results 101 to 110 of about 23,127 (334)

Incretins in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2017
BackgroundThe precise mechanism linking systemic inflammation with insulin resistance (IR) in rheumatoid arthritis (RA) remains elusive. In the present study, we determined whether the incretin-insulin axis and incretin effect are disrupted in patients ...
B. Tejera-Segura, R. López-Mejías, M. Domínguez-Luis, Antonia de Vera-González, A. González-Delgado, B. Ubilla, J. Olmos, J. Hernández, M. González-Gay, I. Ferraz-Amaro   +9 more
semanticscholar   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Studies on Incretins and Cardiovascular Function [PDF]

, 2010
Background Type 2 diabetes (T2DM) is a strong risk factor for coronary heart disease (CHD). A great many diabetic subjects suffer from congestive heart failure (CHF), a condition with a high concomitant mortality.
Nathanson, David
core   +1 more source

Understanding the Incretin Effect [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2011
It is well known that the incretin effect contributes as much as half of the insulin secretory response to oral glucose load and that this effect is reduced along with worsening glucose tolerance in those with type 2 diabetes. Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary incretin hormones secreted from ...
openaire   +2 more sources

Reduced‐Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate whether reduced‐frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy. Methods This retrospective case series included 30 adults who achieved weight plateau while on weekly
Michelle Wong, Ash Wu, Pawanjot K. Garhe, Mitch Biermann   +3 more
wiley   +1 more source

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance

Diabetes, Metabolic Syndrome and Obesity, 2022
Ashwani Sharma,1 Tarun Virmani,1 Anjali Sharma,2 Vaishnavi Chhabra,1 Girish Kumar,1 Kamla Pathak,3 Abdulsalam Alhalmi4 1School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, 121105, India; 2Freelancer, Pharmacovigilance Expert, Uttar ...
Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A   +6 more
doaj  

Metabolic effects of diets differing in glycaemic index depend on age and endogenous GIP [PDF]

, 2009
Aims/hypothesis High- vs low-glycaemic index (GI) diets unfavourably affect body fat mass and metabolic markers in rodents. Different effects of these diets could be age-dependent, as well as mediated, in part, by carbohydrate-induced stimulation of ...
A. Abdelrahman, A. F. Pfeiffer, AR Josse, AW Barclay, B. Thorens, C Yamada, C Zhang, Coon PJ, Rogus EM, Drinkwater D, Muller DC, Goldberg AP, DB Pawlak, DB Pawlak, DS Ludwig, DW Foster, EM Schothorst van, EO Diaz, F Isken, F Isken, F Preitner, F. Isken, J Brand-Miller, J Salmeron, J Salmeron, J Stevens, JA Marshall, JJ Holst, JJ Meier, K Miyawaki, KA Meyer, KB Scribner, KB Scribner, KH Ding, M Kabir, M Lerer-Metzger, M. H. Tschöp, M. Möhlig, M. O. Weickert, MB Schulze, MK Hellerstein, MO Weickert, R. Nogueiras, RM Dam van, S Liu, S. Klaus, SE Byrnes, SJ Gatenby, WM Kohrt, X Pi-Sunyer   +45 more
core   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim, Pooja Gokhale, Akwasi Akosah, Lorenzo Villa‐Zapata   +3 more
wiley   +1 more source

Role of incretin based therapies in the treatment of diabetic kidney disease

Сахарный диабет, 2018
Diabetic kidney disease (DKD), a serious microvascular complication of diabetes mellitus is a leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality.
Paola Fioretto, Andrea Frascati
doaj   +1 more source

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]

, 2019
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada, Iwasaki, Mari, Kaunitz, Jonathan D   +2 more
core